Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future

Karen Mulder, Sheryl Koski, Andrew Scarfe, Quincy Chu, Karen King and Jennifer Spratlin _

PDF  |  HTML  |  How to cite

Oncotarget. 2010; 1:515-529. https://doi.org/10.18632/oncotarget.187

Metrics: PDF 5019 views  |   HTML 3896 views  |   ?  


Received: August 30, 2010, Accepted: October 15, 2010, Published: October 15, 2010

Advanced gastrointestinal (GI) malignancies are varied in presentation, prognosis, and treatment options. With the exception of resectable recurrent colorectal cancer, metastatic GI malignancies are incurable. Cytotoxic chemotherapies have been the mainstay of therapy for decades but limited extension of survival or clinical benefit has been achieved in non-colorectal GI cancers. There has been great interest in the incorporation of antiangiogenic strategies to improve outcomes for these patients. Clear benefits have been identified with bevacizumab and sorafenib in colorectal cancer and hepatocellular cancer, respectively; other GI tumor sites have lacked impressive results with antiangiogenic agents. In this review, we will present the benefits, or lack thereof, of clinically tested antiangiogenic compounds in GI malignancies and explore some potential new therapeutic anti-angiogenesis options for these diseases.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 187